AstraZeneca stock after-hours at EUR 139.55: minus 0.61 percent versus prior close
Published on 10/02/2026 at 18:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock was at EUR 139.55 in after-hours trading at 5:52 p.m. CEST on October 2, 2026, according to Lang & Schwarz. The price was down EUR 0.85, or 0.61 percent, versus the prior close of EUR 140.40 at Lang & Schwarz.
After-hours trading
The October 2 price is separate from the company announcement published on the same date. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of AstraZeneca stock.
Oncology collaboration announced
AstraZeneca said on October 2 that it and Daiichi Sankyo had entered into a clinical collaboration agreement with Summit Therapeutics to evaluate Datroway, or datopotamab deruxtecan, in combination with ivonescimab across multiple tumor types, including lung and breast cancers.
AstraZeneca said the companies intend to begin with a Phase III trial in first-line triple-negative breast cancer. Under the agreement, each company will contribute its respective medicine, AstraZeneca or Daiichi Sankyo will sponsor the planned trials, and the three companies will each contribute to trial costs while retaining development and commercial rights to their respective medicines.
